US › Healthcare

Biovie Inc (BIVI)

US · Healthcare · Biotechnology

$1.20+6.19%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.6M

EPS

$-0.70

EPS estimate

$-0.52

EPS came in at -0.70 against a street estimate of -0.52 — a miss of 34.6%.

Key statistics

Market cap

$10.3M

Forward P/E

0.0

P/B

1.36

Book value

$1.36

EPS (TTM)

$-3.05

52-week high

$3.79

52-week low

$0.82

50-day MA

$1.67

200-day MA

$1.52

Beta

0.73

Analyst view

Analysts rate Biovie Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.25.

Shareholding

Insiders

0.49%

Institutions

22.13%

Largest institutional holders

Fund	Stake
Morgan Stanley - Brokerage Accounts	6.97%
Diametric Capital, LP	2.96%
Renaissance Technologies Corp	1.47%
Citadel Advisors Llc	1.11%
Vanguard Capital Management, LLC	0.82%
Geode Capital Management, LLC	0.81%
Philadelphia Trust Co	0.58%
Vanguard Fiduciary Trust Co	0.43%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biovie Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.